137 related articles for article (PubMed ID: 11109643)
21. Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients.
Anaissie EJ; Fainstein V; Bodey GP; Rolston K; Elting L; Kantarjian H; Cabanillas F; McCredie KB
Am J Med; 1988 Mar; 84(3 Pt 2):581-9. PubMed ID: 3279774
[TBL] [Abstract][Full Text] [Related]
22. An open evaluation of triple antibiotic therapy including vancomycin for febrile bone marrow transplant recipients with severe neutropenia.
Bosi A; Laszlo D; Bacci S; Fanci R; Guidi S; Saccardi R; Vannucchi AM; Rossi-Ferrini P
J Chemother; 1999 Aug; 11(4):287-92. PubMed ID: 10465131
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation.
Egerer G; Goldschmidt H; Salwender H; Hegenbart U; Ehrhard I; Haas R; Ho AD
Int J Antimicrob Agents; 2000 Jul; 15(2):119-23. PubMed ID: 10854807
[TBL] [Abstract][Full Text] [Related]
25. Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides.
Nucci M; Landau M; Silveira F; Spector N; Pulcheri W
Infect Control Hosp Epidemiol; 2001 Oct; 22(10):651-3. PubMed ID: 11776354
[TBL] [Abstract][Full Text] [Related]
26. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients.
Aparicio J; Oltra A; Llorca C; Montalar J; Herranz C; Gómez-Codina J; Pastor M; Munárriz B
Eur J Cancer; 1996 Sep; 32A(10):1739-43. PubMed ID: 8983283
[TBL] [Abstract][Full Text] [Related]
27. Three-step empiric treatment for severely neutropenic patients with fever: ceftazidime--vancomycin--amphotericin B.
Koeppler H; Pflueger KH; Seitz R; Havemann K
Infection; 1989; 17(3):142-5. PubMed ID: 2661438
[TBL] [Abstract][Full Text] [Related]
28. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
[TBL] [Abstract][Full Text] [Related]
29. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer.
Chuang YY; Hung IJ; Yang CP; Jaing TH; Lin TY; Huang YC
Pediatr Infect Dis J; 2002 Mar; 21(3):203-9. PubMed ID: 12005083
[TBL] [Abstract][Full Text] [Related]
30. Ceftazidime with or without vancomycin vs. cephalothin, carbenicillin and gentamicin as the initial therapy of the febrile neutropenic pediatric cancer patient.
Granowetter L; Wells H; Lange BJ
Pediatr Infect Dis J; 1988 Mar; 7(3):165-70. PubMed ID: 3282214
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer.
Chastagner P; Plouvier E; Eyer D; Plesiat P; Lozniewski A; Sommelet D
Med Pediatr Oncol; 2000 Apr; 34(4):306-8. PubMed ID: 10742081
[No Abstract] [Full Text] [Related]
32. [Febrile neutropenia: empiric antibiotic therapy from 1975 to 1997].
Klastersky J
Rev Med Brux; 1997 Oct; 18(5):323-7. PubMed ID: 9441328
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy and safety of vancomycin versus teicoplanin in febrile neutropenic patients receiving hematopoietic stem cell transplantation.
Kato-Hayashi H; Niwa T; Ohata K; Harada S; Matsumoto T; Kitagawa J; Tsurumi H; Suzuki A
J Clin Pharm Ther; 2019 Dec; 44(6):888-894. PubMed ID: 31373043
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia.
Mustafa MM; Carlson L; Tkaczewski I; McCracken GH; Buchanan GR
Pediatr Infect Dis J; 2001 Mar; 20(3):362-9. PubMed ID: 11303851
[TBL] [Abstract][Full Text] [Related]
35. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients.
Wang FD; Liu CY; Hsu HC; Gau JP; Chau WK; Haung ML; Ho CH
Chemotherapy; 1999; 45(5):370-9. PubMed ID: 10473925
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients.
Laszlo D; Bacci S; Bosi A; Fanci R; Guidi S; Saccardi R; Vannucchi AM; Rossi Ferrini P
J Chemother; 1997 Apr; 9(2):95-101. PubMed ID: 9176746
[TBL] [Abstract][Full Text] [Related]
37. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
38. Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients.
Marshall E; Smith DB; O'Reilly SM; Murray A; Kelly V; Clark PI
Support Care Cancer; 2000 May; 8(3):198-202. PubMed ID: 10789960
[TBL] [Abstract][Full Text] [Related]
39. Using teicoplanin for empiric therapy of febrile neutropenic patients with haematological malignancies.
Menichetti F; Del Favero A; Bucaneve G; Aversa F; Fiorio M
Br J Haematol; 1990 Dec; 76 Suppl 2():45-8. PubMed ID: 2149052
[TBL] [Abstract][Full Text] [Related]
40. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation.
D'Antonio D; Staniscia T; Piccolomini R; Fioritoni G; Rotolo S; Parruti G; Di Bonaventura G; Manna A; Savini V; Fiorilli MP; Di Giovanni P; Francione A; Schioppa F; Romano F
Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
